CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1

[1]  Y. Li,et al.  PD-1+ CD8+ T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients , 2014, British Journal of Cancer.

[2]  Jean Daudelin,et al.  Notch signaling regulates PD‐1 expression during CD8+ T‐cell activation , 2013, Immunology and cell biology.

[3]  H. Einsele,et al.  Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. , 2012, Blood.

[4]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[5]  Andreas Wolf,et al.  Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. , 2012, Blood.

[6]  Antoni Ribas,et al.  Tumor immunotherapy directed at PD-1. , 2012, The New England journal of medicine.

[7]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[8]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[9]  Jenna M. Sullivan,et al.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2010, The Journal of experimental medicine.

[10]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[11]  D. Olive,et al.  PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. , 2010, International immunology.

[12]  J. Allison,et al.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.

[13]  S. Enerbäck,et al.  Pilot Study of Sentinel-Node-Based Adoptive Immunotherapy in Advanced Colorectal Cancer , 2010, Annals of Surgical Oncology.

[14]  D. Hsu,et al.  Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody , 2009, British Journal of Cancer.

[15]  Carsten Reinhardt,et al.  Bispecific T-cell engaging antibodies for cancer therapy. , 2009, Cancer research.

[16]  R. Kischel,et al.  Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA , 2009, Journal of immunotherapy.

[17]  H. Einsele,et al.  Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.

[18]  D. Gabrilovich,et al.  Tumor escape mechanism governed by myeloid-derived suppressor cells. , 2008, Cancer research.

[19]  Scott N. Mueller,et al.  Enhancing therapeutic vaccination by blocking PD-1–mediated inhibitory signals during chronic infection , 2008, The Journal of experimental medicine.

[20]  P. Kufer,et al.  Strictly Target Cell-dependent Activation of T Cells by Bispecific Single-chain Antibody Constructs of the BiTE Class , 2007 .

[21]  T. Whiteside,et al.  Tumor microenvironment and immune escape. , 2007, Surgical oncology clinics of North America.

[22]  G. Freeman,et al.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.

[23]  Loise M. Francisco,et al.  PD-1 and its ligands in T-cell immunity. , 2007, Current opinion in immunology.

[24]  G. Freeman,et al.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection , 2007, Nature Immunology.

[25]  P. Kufer,et al.  Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. , 2006, Journal of immunotherapy.

[26]  R. Kimmig,et al.  MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. , 2006, Molecular immunology.

[27]  Lieping Chen,et al.  Interferon regulatory factor‐1 is prerequisite to the constitutive expression and IFN‐γ‐induced upregulation of B7‐H1 (CD274) , 2006, FEBS letters.

[28]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[29]  H. Mellstedt,et al.  Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  Steven A. Rosenberg,et al.  Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients , 2003, Journal of immunotherapy.

[31]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[32]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[34]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[35]  S. Egawa,et al.  Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer , 2000, The British journal of surgery.

[36]  S. Hammarström.  The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. , 1999, Seminars in cancer biology.

[37]  野見 武男.  Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer , 2007 .

[38]  A. Balmain,et al.  TGF-beta signaling in tumor suppression and cancer progression. , 2001, Nature genetics.